Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019
Abstract Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID‐19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID‐19 treatments....
Main Authors: | Pattara Rattanawong, Win Shen, Hicham El Masry, Dan Sorajja, Komandoor Srivathsan, Arturo Valverde, Luis R. Scott |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-07-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.017529 |
Similar Items
-
Pharmacologic Therapy in the Elderly with Atrial Fibrillation
by: Shih-Huang Lee, et al.
Published: (2008-03-01) -
Transvenous, intracardial cardioversion for the treatment of postoperative atrial fibrillation
by: Fitzgerald Robert, et al.
Published: (2008-01-01) -
ATRIAL FIBRILLATION: CURRENT PROBLEMS AND PROSPECTS OF MEDICAL CARE, TREATMENT AND PREVENTION
by: Ju. P. Skirdenko, et al.
Published: (2016-05-01) -
Personalized Medicine in the Treatment of Atrial Fibrillation: Myth or Reality?
by: V. I. Podzolkov, et al.
Published: (2019-03-01) -
Comparative Effectiveness of Aksaritmin and Propafenone in the Prevention of Atrial Fibrillation
by: Husniddin Sh. Kuchkarov, et al.
Published: (2023-06-01)